Annual Cash & Cash Equivalents
$175.53 M
+$155.00 M+755.20%
December 31, 2023
Summary
- As of February 7, 2025, ATXS annual cash & cash equivalents is $175.53 million, with the most recent change of +$155.00 million (+755.20%) on December 31, 2023.
- During the last 3 years, ATXS annual cash & cash equivalents has risen by +$150.60 million (+604.09%).
- ATXS annual cash & cash equivalents is now at all-time high.
Performance
ATXS Cash And Cash Equivalents Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly Cash And Cash Equivalents
$80.90 M
-$6.31 M-7.24%
September 30, 2024
Summary
- As of February 7, 2025, ATXS quarterly cash and cash equivalents is $80.90 million, with the most recent change of -$6.31 million (-7.24%) on September 30, 2024.
- Over the past year, ATXS quarterly cash and cash equivalents has dropped by -$38.91 million (-32.48%).
- ATXS quarterly cash and cash equivalents is now -60.01% below its all-time high of $202.30 million, reached on March 31, 2023.
Performance
ATXS Quarterly Cash And Cash Equivalents Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Cash And Cash Equivalents Formula
Cash & Cash Equivalents = Cash + Short-Term Investments
ATXS Cash And Cash Equivalents Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly |
|---|---|---|
| 1 y1 year | +755.2% | -32.5% |
| 3 y3 years | +604.1% | -32.5% |
| 5 y5 years | +1047.7% | -32.5% |
ATXS Cash And Cash Equivalents Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | |
|---|---|---|---|---|---|
| 3 y | 3-year | at high | +755.2% | -60.0% | +294.1% |
| 5 y | 5-year | at high | +1673.2% | -60.0% | +717.2% |
| alltime | all time | at high | +1673.2% | -60.0% | +741.4% |
Astria Therapeutics Cash And Cash Equivalents History
| Date | Annual | Quarterly |
|---|---|---|
| Sep 2024 | - | $80.90 M(-7.2%) |
| Jun 2024 | - | $87.21 M(-49.3%) |
| Mar 2024 | - | $172.01 M(-2.0%) |
| Dec 2023 | $175.53 M(+755.2%) | $175.53 M(+46.5%) |
| Sep 2023 | - | $119.81 M(-10.6%) |
| Jun 2023 | - | $133.96 M(-33.8%) |
| Mar 2023 | - | $202.30 M(+885.6%) |
| Dec 2022 | $20.52 M(-76.3%) | $20.52 M(-55.4%) |
| Sep 2022 | - | $45.97 M(+54.1%) |
| Jun 2022 | - | $29.83 M(-36.1%) |
| Mar 2022 | - | $46.69 M(-46.0%) |
| Dec 2021 | $86.51 M(+247.0%) | $86.51 M(-34.4%) |
| Sep 2021 | - | $131.78 M(-5.5%) |
| Jun 2021 | - | $139.52 M(-5.0%) |
| Mar 2021 | - | $146.92 M(+489.3%) |
| Dec 2020 | $24.93 M(+151.8%) | $24.93 M(-52.8%) |
| Sep 2020 | - | $52.86 M(+1.9%) |
| Jun 2020 | - | $51.88 M(+288.8%) |
| Mar 2020 | - | $13.34 M(+34.8%) |
| Dec 2019 | $9.90 M | $9.90 M(-44.3%) |
| Date | Annual | Quarterly |
|---|---|---|
| Sep 2019 | - | $17.77 M(+84.8%) |
| Jun 2019 | - | $9.62 M(-17.5%) |
| Mar 2019 | - | $11.65 M(-23.8%) |
| Dec 2018 | $15.29 M(-6.6%) | $15.29 M(-23.1%) |
| Sep 2018 | - | $19.88 M(-60.2%) |
| Jun 2018 | - | $49.93 M(+193.2%) |
| Mar 2018 | - | $17.03 M(+4.0%) |
| Dec 2017 | $16.37 M(-30.6%) | $16.37 M(-24.6%) |
| Sep 2017 | - | $21.71 M(-26.1%) |
| Jun 2017 | - | $29.37 M(-7.6%) |
| Mar 2017 | - | $31.80 M(+34.7%) |
| Dec 2016 | $23.60 M(-62.4%) | $23.60 M(-10.8%) |
| Sep 2016 | - | $26.46 M(+9.0%) |
| Jun 2016 | - | $24.28 M(+1.9%) |
| Mar 2016 | - | $23.82 M(-62.1%) |
| Dec 2015 | $62.78 M(+328.0%) | $62.78 M(-13.7%) |
| Sep 2015 | - | $72.71 M(-10.8%) |
| Jun 2015 | - | $81.55 M(+235.5%) |
| Mar 2015 | - | $24.30 M(+65.7%) |
| Dec 2014 | $14.67 M(-51.9%) | $14.67 M |
| Dec 2013 | $30.47 M | - |
FAQ
- What is Astria Therapeutics annual cash & cash equivalents?
- What is the all time high annual cash & cash equivalents for Astria Therapeutics?
- What is Astria Therapeutics annual cash & cash equivalents year-on-year change?
- What is Astria Therapeutics quarterly cash and cash equivalents?
- What is the all time high quarterly cash and cash equivalents for Astria Therapeutics?
- What is Astria Therapeutics quarterly cash and cash equivalents year-on-year change?
What is Astria Therapeutics annual cash & cash equivalents?
The current annual cash & cash equivalents of ATXS is $175.53 M
What is the all time high annual cash & cash equivalents for Astria Therapeutics?
Astria Therapeutics all-time high annual cash & cash equivalents is $175.53 M
What is Astria Therapeutics annual cash & cash equivalents year-on-year change?
Over the past year, ATXS annual cash & cash equivalents has changed by +$155.00 M (+755.20%)
What is Astria Therapeutics quarterly cash and cash equivalents?
The current quarterly cash and cash equivalents of ATXS is $80.90 M
What is the all time high quarterly cash and cash equivalents for Astria Therapeutics?
Astria Therapeutics all-time high quarterly cash and cash equivalents is $202.30 M
What is Astria Therapeutics quarterly cash and cash equivalents year-on-year change?
Over the past year, ATXS quarterly cash and cash equivalents has changed by -$38.91 M (-32.48%)